Monday, Dec 02, 2019 9:00a -
Wednesday, Dec 04, 2019 5:00p
The Westin Copley Place, Boston
10 Huntington Avenue
Boston, MA 02116
$2899 - 3999
Lectures & Conferences
At a time when the previously untapped drug discovery opportunity promised within RNA opens up, the 2nd RNA- Targeted Drug Discovery Summit returns to reunite the leading minds from large pharma, innovative biotech and KOLs of academia to discuss unique discovery and development challenges that must be overcome for novel RNA targeted small molecule therapeutics to achieve their seemingly limitless potential.
For the 2nd year, network with the KOLs and RNA pioneers, to gain a comprehensive understanding on how to translate the first generation of RNA targeted small molecules into the clinic, stimulate the discussion of successfully targeting RNA via interfering with RNA-protein interactions and seize the therapeutic opportunity in hand by re-defining the undruggable nature of RNA.
Conference full access (includes workshops) - Early birds available: USD 3999.00
Conference only - Early birds available: USD 2899.00
Speakers: Jane Withka, Director and Collaboration Lead, Pfizer Worldwide RandD, Samie R. Jaffrey, Co-Founder of Gotham Therapeutics; Professor of Pharmacology, Weill Cornell Medicine, Jennifer Petter, Founder and CSO, Arrakis Therapeutics, Richard Gregory Co-Founder of Twentyeight- Seven Therapeutics; Professor Boston Children’s Hospital/Harvard Medical School, Kathryn McCabe Senior Director of Business Development- Emerging Technology and Innovation Eli Lilly, Yochi Slonim Co-Founder and CEO Anima Biotech, Margaret Porter Scott VP, Biochemical and Cellular Pharmacology Genentech, Frank Slack Co-Founder of Twentyeight- Seven Therapeutics; Professor of Pathology Beth Israel Deaconess Medical Center, Razvan Nutiu Senior Investigator Novartis, Wesley Blackaby VP, Chemistry Storm Therapeutics, Kevin Weeks Founder of Ribometrix; Professor of Chemistry University of North Carolina, Martin Pettersson Research Fellow Pfizer, George A. Calin Professor, Department of Experimental Therapeutics The University of Texas MD Anderson Cancer Center, Johan Pontin Founder and Former CEO The RNA Medicines Company, Christopher Barbieri Senior Investigator Bristol-Myers Squibb, Gerhard Mueller CSO Gotham Therapeutics, Ann Boriack-Sjodin VP, Molecular Discovery Accent Therapeutics, Christopher R. Trotta VP, Biology PTC Therapeutics, Pramod Pandey Principal Scientist Merck Research Labs Exploratory Science Center, Gabriele Varani Professor of Chemistry University of Washington, John Schneekloth Senior Investigator National Cancer Institute, Julius B. Lucks Associate Professor Northwestern University, Pawel Sledz Senior Scientist and Project Manager University of Zurich, John Moffat Senior Scientist, Biochemical and Cellular Pharmacology Genentech